ATE171073T1 - Pharmazeutische zusammensetzung für ortsspezifische abgabe von blutgerinselauflösende proteine - Google Patents

Pharmazeutische zusammensetzung für ortsspezifische abgabe von blutgerinselauflösende proteine

Info

Publication number
ATE171073T1
ATE171073T1 AT93923685T AT93923685T ATE171073T1 AT E171073 T1 ATE171073 T1 AT E171073T1 AT 93923685 T AT93923685 T AT 93923685T AT 93923685 T AT93923685 T AT 93923685T AT E171073 T1 ATE171073 T1 AT E171073T1
Authority
AT
Austria
Prior art keywords
plasminogen
pharmaceutical composition
liposomes
site
composition
Prior art date
Application number
AT93923685T
Other languages
English (en)
Inventor
Johanna Louise Maria Heeremans
Cornelis Kluft
Daniel Jan Anne Grommelin
Original Assignee
Stichting Tech Wetenschapp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Tech Wetenschapp filed Critical Stichting Tech Wetenschapp
Application granted granted Critical
Publication of ATE171073T1 publication Critical patent/ATE171073T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Actuator (AREA)
  • Structures Of Non-Positive Displacement Pumps (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT93923685T 1992-10-05 1993-10-05 Pharmazeutische zusammensetzung für ortsspezifische abgabe von blutgerinselauflösende proteine ATE171073T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL9201722A NL9201722A (nl) 1992-10-05 1992-10-05 Farmaceutische samenstelling voor de plaatsgebonden afgifte van een stolsel oplossend eiwit en werkwijze voor de bereiding daarvan.

Publications (1)

Publication Number Publication Date
ATE171073T1 true ATE171073T1 (de) 1998-10-15

Family

ID=19861342

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93923685T ATE171073T1 (de) 1992-10-05 1993-10-05 Pharmazeutische zusammensetzung für ortsspezifische abgabe von blutgerinselauflösende proteine

Country Status (9)

Country Link
EP (1) EP0662841B1 (de)
JP (1) JPH08502060A (de)
AT (1) ATE171073T1 (de)
AU (1) AU5345494A (de)
CA (1) CA2146324A1 (de)
DE (1) DE69321131D1 (de)
NL (1) NL9201722A (de)
NO (1) NO951219L (de)
WO (1) WO1994007537A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220233A1 (en) 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
DE19529223A1 (de) * 1995-08-09 1997-02-13 Boehringer Mannheim Gmbh Verwendung von Plasminogenaktivatoren zum lokalen Knochenaufbau
KR102897177B1 (ko) * 2019-04-12 2025-12-05 유지엘엑스 리서치 에이비 장기 복구를 위한 방법 및 장치
EP3952644B1 (de) * 2019-04-12 2025-09-24 UGLK Science AB Verfahren und vorrichtung zur rekonditionierung von nieren

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE831867A (fr) * 1975-07-29 1976-01-29 Association d'un activateur du plasminogene, d'une part, et du plasminogene lui-meme
JPS52102975A (en) * 1976-02-24 1977-08-29 Toyota Motor Corp Hydraulic driving system
US4193983A (en) * 1978-05-16 1980-03-18 Syva Company Labeled liposome particle compositions and immunoassays therewith
DE3682754D1 (de) * 1985-12-16 1992-01-16 Ethicon Inc Hemmung von post-chirurgischer adhaesionsbildung durch topische verabreichung von gewebeplasminogenaktivator.
US5000960A (en) * 1987-03-13 1991-03-19 Micro-Pak, Inc. Protein coupling to lipid vesicles
JP2764264B2 (ja) * 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time

Also Published As

Publication number Publication date
AU5345494A (en) 1994-04-26
CA2146324A1 (en) 1994-04-14
NO951219L (no) 1995-06-06
EP0662841B1 (de) 1998-09-16
JPH08502060A (ja) 1996-03-05
NO951219D0 (no) 1995-03-30
DE69321131D1 (de) 1998-10-22
EP0662841A1 (de) 1995-07-19
WO1994007537A1 (en) 1994-04-14
NL9201722A (nl) 1994-05-02

Similar Documents

Publication Publication Date Title
US6355243B1 (en) Method of thrombolysis by local delivery of active plasmin
Giles et al. A combination of factor Xa and phosphatidylcholine‐phosphatidylserine vesicles bypasses factor VIII in vivo
Broze Binding of human factor VII and VIIa to monocytes.
DE69323195T2 (de) VERKÜRZTER GEWEBSFAKTOR UND FVIIa ODER FVII ZUR AKTIVIERUNG DER BLUTGERINNUNG
Monroe et al. Platelet activity of high‐dose factor VIIa is independent of tissue factor
EP0968008B1 (de) Stabilisierte mischung auf fibrinogenbasis
CN1182879C (zh) 一种含纤维蛋白原的稳定化混合物
EP0333740B1 (de) Pharmazeutisch aktive konjugate mit spezifität für die bindung an körpergewebe
CA2200394A1 (en) A pharmaceutical preparation for treating blood coagulation disorders
ATE279430T1 (de) Verfahren zur verbesserung der serum halbwertszeit von biologisch aktiven molekülen
Levin et al. Specificity of the thrombin-induced release of tissue plasminogen activator from cultured human endothelial cells
Hedner et al. Clinical Experience with Human Plasma-Derived Factor VIla in Patients with Hemophilia A and High Titer Inhibitors
ES2183805T3 (es) Procedimiento de preparacion de un medicamento trombolitico.
DK0477274T3 (da) Faktor Xa baserede antikoaguleringspræparater
Bishop et al. Comparison of recombinant human thrombin and plasma-derived human α-thrombin
JP2820699B2 (ja) 血栓溶解剤
US5023078A (en) Plasminogen activator-heparin conjugates
Swenson et al. α-Fibrinogenases
US20030175264A1 (en) Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
DE69321131D1 (de) Pharmazeutische zusammensetzung für ortsspezifische abgabe von blutgerinselauflösende proteine
Wintroub et al. Cleavage of fibrinogen by the human neutrophil neutral peptide-generating protease.
de Serrano et al. Influence of various structural domains of fibrinogen and fibrin on the potentiation of plasminogen activation by recombinant tissue plasminogen activator
US5091363A (en) Agent for the therapy of factor viii-resistant hemophilia a, and a process for the preparation thereof
EP0253582A1 (de) Modifizierter Gewebsplasminogenaktivator
Bachmann Fibrinolytic agents